Yesterday, the Supreme Court of the United States upheld important safety protocols for chemical abortions. The Food and Drug Administration’s rule requires a woman to have an in-person doctor’s visit before undergoing a chemical (“medication”) abortion during the COVID-19 pandemic.
“The Supreme Court was right to uphold the minimum safety protocols for chemical abortions,” says Lois Anderson, executive director. “In the pursuit of profit, the abortion industry continues to push to eliminate protections for women, to tragic results.”
The FDA has recorded nearly two dozen deaths and thousands of complications, including “adverse events” such as serious infections, severe hemorrhage, and the rupture of undiscovered ectopic pregnancies since mifepristone was approved for use in chemical abortions.
Under the FDA’s “Risk Evaluation and Mitigation Strategy” (REMS), only FDA-approved entities can distribute mifepristone, one of the two drugs that make up the medication abortion technique.
When the FDA approved mifepristone as an abortion method, REMS restrictions were put in place because women face potentially life-threatening complications that have been associated with the use of the drug.